antituberculosis drug

antituberculosis drug

Infectious disease Any drug–eg, isoniazid, rifampin, ethambutol, streptomycin, pyrazinamide, ethionamide, para-aminosalicylic acid, kanamycin, cycloserine, capreomycin, ciprofloxacin, amikacin, used to manage TB; multidrug-resistant isolates of M tuberculosis are most often resistant to isoniazid and rifampin. See Drug-resistant tuberculosis.
References in periodicals archive ?
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drugs resistance surveillance.
LJ medium impregnated one antituberculosis drug was used for DST and the critical drug concentrations were 0.
tuberculosis infection resistant to a single antituberculosis drug, MDR-TB as resistant to both isoniazid and rifampicin, and poly-resistant TB as resistant to more than one anti-tuberculosis drug (other than the combination of isoniazid and rifampicin).
of risk factors for hepatotoxicity in patients with antituberculosis drug induced hepatitis.
Global Project on Antituberculosis Drug Resistance Surveillance: Antituberculosis Drug Resistance in the World.
Substandard TB drugs are readily available in the private marketplace and probably contribute to antituberculosis drug resistance in low- and middle-income countries--and possibly the richer world too.
Monitoring and management of antituberculosis drug induced hepatotoxicity.
In 1952, doctors noted that patients on the antituberculosis drug iproniazid became euphoric.
If approved by the FDA, bedaquiline will be the first antituberculosis drug with a novel mechanism of action approved in the United States since rifampin's approval in 1970, and the first drug approved for TB since rifapentine was approved in 1998.
Inclusion criteria were at least 30 days of treatment with a second-line antituberculosis drug, with sputum collection within 30 days before or after the initiation of therapy.
13 According to the World Health Organization (WHO) International Union against Tuberculosis and Lung Disease working group report on global surveillance for antituberculosis drug resistance, the prevalence of primary MDR and acquired resistance in previously treated patients is 1.